Free CBIC CIC Practice Exam with Questions & Answers | Set: 7

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that accurate comparison of healthcare-associated infection risk between groups requires use of standardized, exposure-based rates. For central line–associated bloodstream infections (CLABSIs), the recommended metric is infections per 1,000 central line days, which accounts for the amount of time patients are actually exposed to the risk factor—in this case, the presence of a central venous catheter.

Patients receiving TPN at home and those receiving TPN in the hospital may differ substantially in duration of catheter use, care practices, and patient acuity. Simply comparing percentages or raw numbers of infections fails to adjust for differences in central line utilization and can result in misleading conclusions. By using central line days as the denominator, infection rates are normalized and allow for valid comparisons between populations and settings.

Option A does not account for differences in exposure time. Option C compares different time periods rather than comparing risk between groups. Option D provides a ratio but lacks standardization and is not consistent with accepted surveillance methodology.

The Study Guide reinforces that device-associated infection surveillance—such as CLABSI monitoring—must use device days to assess true risk and guide prevention strategies. Understanding and applying correct epidemiologic measures is a core competency for infection preventionists and a frequently tested concept on the CIC® exam.

==========

The pneumococcal vaccine is designed to protect against infections caused by Streptococcus pneumoniae, a bacterium responsible for diseases such as pneumonia, meningitis, and bacteremia. The appropriateness of this vaccine depends on the population's risk profile, particularly their susceptibility to invasive pneumococcal disease (IPD). The Certification Board of Infection Control and Epidemiology (CBIC) highlights the role of infection preventionists as educators in promoting vaccination as a key risk reduction strategy, aligning with the "Education and Training" domain (CBIC Practice Analysis, 2022). The Centers for Disease Control and Prevention (CDC) provides specific guidelines on pneumococcal vaccination, recommending it for individuals at higher risk due to underlying medical conditions or immunologic status.

Option A, asplenic patients, refers to individuals who have had their spleen removed (e.g., due to trauma or disease) or have a nonfunctional spleen (e.g., in sickle cell disease). The spleen plays a critical role in clearing encapsulated bacteria like Streptococcus pneumoniae from the bloodstream. Without a functioning spleen, these patients are at significantly increased risk of overwhelming post-splenectomy infection (OPSI), with pneumococcal disease being a leading cause. The CDC and Advisory Committee on Immunization Practices (ACIP) strongly recommend pneumococcal vaccination, including both PCV15/PCV20 and PPSV23, for asplenic patients, making this group the most appropriate for the vaccine in this context. The infection preventionist should prioritize educating these patients and their families about the vaccine's importance and timing.

Option B, international travelers, may benefit from various vaccines depending on their destination (e.g., yellow fever or typhoid), but pneumococcal vaccination is not routinely recommended unless they have specific risk factors (e.g., asplenia or chronic illness) or are traveling to areas with high pneumococcal disease prevalence. This group is not inherently a priority for pneumococcal vaccination. Option C, immunocompromised newborns, includes infants with congenital immunodeficiencies or other conditions, who may indeed require pneumococcal vaccination as part of their routine immunization schedule (e.g., PCV15 or PCV20 starting at 2 months). However, newborns are generally covered under universal childhood vaccination programs, and the question’s focus on "MOST appropriate" suggests a group with a more specific, elevated risk, which asplenic patients fulfill. Option D, patients in behavioral health settings, may have varied health statuses, but this group is not specifically targeted for pneumococcal vaccination unless they have additional risk factors (e.g., chronic diseases), making it less appropriate than asplenic patients.

The CBIC emphasizes tailoring education to high-risk populations, and the CDC’s Adult and Pediatric Immunization Schedules (2023) identify asplenic individuals as a top priority for pneumococcal vaccination due to their extreme vulnerability. Thus, the infection preventionist should focus on asplenic patients as the group for whom the pneumococcal vaccine is most appropriate.

The Certification Study Guide (6th edition) emphasizes that an outbreak should be suspected when there is an unexpected clustering of infections by time, place, and person, particularly when cases share a common exposure or procedure. Option D meets all key criteria for outbreak suspicion: the same organism (methicillin-resistant Staphylococcus aureus), the same location (cardiac ICU), a common procedure (cardiac surgery), and a tight time frame (same week). This constellation strongly suggests possible transmission related to surgical practices, postoperative care, or shared equipment.

The other scenarios reflect situations that do not necessarily indicate an outbreak. Routine environmental cultures are not recommended for outbreak detection and often do not correlate with patient infection risk. An apparent increase in ventilator-associated pneumonia following implementation of a new case definition is likely due to surveillance artifact, not true transmission. Similarly, increases in carbapenemase-producing Klebsiella pneumoniae after adoption of new laboratory breakpoints reflect diagnostic changes, not an epidemiologic event.

The study guide stresses the importance of distinguishing true outbreaks from pseudo-outbreaks caused by changes in definitions, testing methods, or surveillance intensity. CIC exam questions frequently test this concept. Recognizing a true outbreak requires linking cases through epidemiologic characteristics—not simply increases in numbers.

Prompt recognition of true outbreaks enables timely investigation, implementation of control measures, and prevention of further transmission.

The safe transport of biohazardous samples, such as infectious agents, clinical specimens, or diagnostic materials, is a critical aspect of infection prevention and control to prevent exposure and environmental contamination. The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes adherence to regulatory and safety standards in the "Prevention and Control of Infectious Diseases" domain, which includes proper handling and shipping of biohazardous materials. The primary guideline governing this practice is the U.S. Department of Transportation (DOT) Hazardous Materials Regulations (HMR) and the International Air Transport Association (IATA) Dangerous Goods Regulations, which align with global biosafety standards.

Option A, "Ship using triple-containment packaging," is the essential element of practice. Triple-containment packaging involves three layers: a primary watertight container holding the sample, a secondary leak-proof container with absorbent material, and an outer rigid packaging (e.g., a box) that meets shipping regulations. This system ensures that biohazardous materials remain secure during transport, preventing leaks or breaches that could expose handlers or the public. The CDC and WHO endorse this method as a fundamental requirement for shipping Category A (high-risk) and Category B (moderate-risk) infectious substances, making it the cornerstone of safe transport practice.

Option B, "Electronically log and send via overnight delivery," is a useful administrative and logistical step to track shipments and ensure timely delivery, but it is not the essential element. While documentation and rapid delivery are important for maintaining chain of custody and sample integrity, they are secondary to the physical containment provided by triple packaging. Option C, "Transport by an authorized biohazard transporter," is a necessary step to comply with regulations, as only trained and certified transporters can handle biohazardous materials. However, this is contingent on proper packaging; without triple containment, transport authorization alone is insufficient. Option D, "Store in a cooler that is labeled as a health hazard," may be part of preparation (e.g., maintaining sample temperature), but labeling alone does not address the containment or transport safety required during shipment. Coolers are often used, but the focus on labeling as a health hazard is incomplete without the triple-containment structure.

The CBIC Practice Analysis (2022) supports compliance with federal and international shipping regulations, which prioritize triple-containment packaging as the foundational practice to mitigate risks. The CDC’s Biosafety in Microbiological and Biomedical Laboratories (BMBL, 6th Edition, 2020) and IATA guidelines further specify that triple packaging is mandatory for all biohazardous shipments, reinforcing Option A as the correct answer.

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that when a device recall involves potential contamination risk, the infection preventionist’s first priority is risk mitigation and prevention of further exposure. In this scenario, the recall of ice machines due to a faulty filtration device represents a potential waterborne contamination risk, even in the absence of confirmed infections.

The best immediate action is to remove the recalled ice machines from service and provide an alternative source of ice while further investigation and corrective actions are underway. This step promptly eliminates the exposure pathway and protects patients, staff, and visitors from possible contamination. The Study Guide stresses that interruption of use is the most effective initial control measure when equipment safety is in question.

Option A is incorrect because culturing ice machines is not the first step and is not routinely recommended without clinical indication. Option B is inappropriate because there is no evidence of a confirmed outbreak. Option C may be necessary later if exposure investigation becomes warranted, but it should not precede immediate risk control.

For the CIC® exam, it is essential to recognize that eliminating exposure takes precedence over testing or notification activities. Supplying an alternative ice source while investigating further aligns with risk management principles, patient safety priorities, and evidence-based infection prevention practice.

==========

The CBIC Certified Infection Control Exam Study Guide (6th edition) explains that the effectiveness of disinfection depends on multiple physical, chemical, and biologic factors, but virulence of the organism is not one of them. Virulence refers to an organism’s ability to cause disease in a host, which is a clinical characteristic, not a determinant of susceptibility to disinfectants.

Disinfection efficacy is influenced by factors such as the type and number of microorganisms, particularly their intrinsic resistance (for example, spores are more resistant than vegetative bacteria), making option C a true determinant. The amount of organic material present (option B) is also critical, as organic matter can inactivate disinfectants or shield microorganisms from exposure. Likewise, the length of exposure (contact time) to the chemical agent (option D) is essential to achieving the desired level of microbial kill and is specified in manufacturer instructions for use.

Virulence does not affect how easily an organism is destroyed by a disinfectant. For example, a highly virulent organism may be easily killed by a low-level disinfectant, while a less virulent organism such as a bacterial spore may be highly resistant. Therefore, virulence plays no role in determining disinfection effectiveness.

For CIC® exam preparation, it is important to distinguish between clinical severity and microbial resistance. Disinfection effectiveness is based on resistance characteristics and process variables—not on how dangerous the organism is to humans.

The CBIC Certified Infection Control Exam Study Guide (6th edition) highlights that consumption of raw or undercooked shellfish, particularly imported shellfish, is a well-recognized risk factor for waterborne and foodborne Vibrio infections, including Vibrio cholerae. The organism thrives in warm coastal waters and can contaminate shellfish harvested from endemic or inadequately regulated regions.

The clinical presentation described—profuse watery diarrhea occurring approximately 48 hours after exposure—is classic for Vibrio cholerae. The organism produces cholera toxin, which causes rapid fluid secretion into the intestinal lumen, resulting in large-volume watery stools. The incubation period typically ranges from a few hours to five days, making a 48-hour onset highly consistent with this pathogen.

The other options are less likely based on incubation period and symptom profile. Hepatitis A virus has an incubation period of weeks and presents with jaundice rather than acute watery diarrhea. Staphylococcus aureus food poisoning causes rapid onset (1–6 hours) due to preformed toxin and is commonly associated with vomiting. Listeria monocytogenes typically causes invasive disease rather than acute watery diarrhea and has a longer incubation period.

For CIC® exam preparation, recognizing shellfish-associated watery diarrhea with short incubation as characteristic of Vibrio cholerae is essential, particularly in outbreak investigations involving imported seafood.

The correct answer is B, "The sterility is not maintained during storage," as this represents a key limitation of using liquid chemical sterilants to sterilize medical items. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines and standards from the Association for the Advancement of Medical Instrumentation (AAMI), liquid chemical sterilants, such as glutaraldehyde or peracetic acid, are effective for sterilizing heat-sensitive medical devices by eliminating all forms of microbial life, including spores, when used according to manufacturer instructions (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). However, a significant limitation is that sterility is not guaranteed after the items are removed from the sterilant and stored, as the sterile barrier can be compromised by environmental contamination, improper packaging, or handling (AAMI ST58:2013, Chemical Sterilization and High-Level Disinfection in Health Care Facilities).

Option A (it does not kill the spores) is incorrect because liquid chemical sterilants are designed to achieve sterilization, including the destruction of bacterial spores, provided the contact time, concentration, and conditions specified by the manufacturer are met. Option C (it requires a contact time of at least 12 hours) is not a universal limitation; while some liquid sterilants require extended contact times (e.g., 10-12 hours for certain formulations), this is a procedural requirement rather than an inherent limitation, and shorter times may be sufficient with other agents or automated systems. Option D (it can only be used for heat tolerant devices) is incorrect because liquid chemical sterilants are specifically intended for heat-sensitive devices that cannot withstand steam or dry heat sterilization.

The limitation of sterility not being maintained during storage underscores the need for immediate use of sterilized items or the use of proper sterile packaging and storage protocols to prevent recontamination. This aligns with CBIC’s focus on ensuring the safety and efficacy of reprocessed medical equipment in infection prevention (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). Healthcare facilities must implement strict post-sterilization handling and storage practices to mitigate this limitation.

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes the importance of distinguishing colonization from infection when interpreting microbiology results. Colonization refers to the presence of microorganisms on or within the body without causing clinical signs or symptoms of disease. In older adults, especially those in healthcare settings, asymptomatic bacteriuria is common and does not meet criteria for a urinary tract infection (UTI).

In this scenario, the presence of Enterococcus faecium in a urine culture in the absence of urinary symptoms—such as dysuria, urgency, fever, or suprapubic pain—indicates colonization rather than infection. The Study Guide notes that treating asymptomatic bacteriuria does not improve patient outcomes and may contribute to antimicrobial resistance, adverse drug events, and unnecessary healthcare costs. Therefore, antibiotics are not indicated.

Option A is incorrect because Enterococcus species are not transmitted via the airborne route; Standard Precautions are sufficient. Option B is incorrect because laboratory findings alone do not define infection without corresponding clinical symptoms. Option D is less accurate because contamination is more likely with mixed flora or improper collection; isolation of a known urinary colonizer in an asymptomatic patient is more consistent with colonization.

Accurate interpretation of such findings supports antimicrobial stewardship principles and aligns with evidence-based infection prevention practices tested on the CIC® exam.

==========

The Certification Study Guide (6th edition) classifies endovaginal ultrasound probes as semi-critical devices because they come into contact with mucous membranes. As such, they require high-level disinfection (HLD) between patients, not sterilization, unless the manufacturer specifically requires it. This immediately eliminates option A, which incorrectly states sterilization is required.

Option B is incorrect because probe covers or sheaths do not eliminate the risk of contamination. Numerous studies referenced in infection prevention literature and reflected in the study guide demonstrate that probe covers can fail, tear, or leak, allowing microorganisms—including viruses—to contaminate the probe surface. Therefore, HLD is required regardless of sheath use.

Option C is incorrect because critical items, by definition, enter sterile tissue or the vascular system. Endovaginal probes contact mucous membranes only and are therefore not critical items under the Spaulding Classification System.

Option D is correct because endovaginal probes may be contaminated with human papillomavirus (HPV) prior to examination, even when probe covers are used. HPV is particularly concerning due to its resistance to some low-level disinfectants and its ability to persist on surfaces. The study guide highlights HPV as a key organism driving strict reprocessing requirements for these probes.

This question reflects a high-yield CIC exam concept: probe covers do not replace high-level disinfection, and viral contamination—including HPV—remains a significant risk.